Ajanta Pharma Limited (NSE: AJANTPHARM)
India
· Delayed Price · Currency is INR 2,803.75
-1.75 (-0.06%)
Dec 24, 2024, 3:30 PM IST
Ajanta Pharma Revenue
Ajanta Pharma had revenue of 11.87B INR in the quarter ending September 30, 2024, with 15.38% growth. This brings the company's revenue in the last twelve months to 44.91B, up 15.06% year-over-year. In the fiscal year ending March 31, 2024, Ajanta Pharma had annual revenue of 42.09B with 12.45% growth.
Revenue (ttm)
44.91B
Revenue Growth
+15.06%
P/S Ratio
7.84
Revenue / Employee
5.56M
Employees
8,073
Market Cap
350.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | 25.88B | 5.33B | 25.91% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAjanta Pharma News
- 21 days ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 2 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn
- 2 months ago - Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore - Business Upturn
- 2 months ago - Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83% - Business Upturn
- 2 months ago - Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance - Business Upturn